医疗IT业务稳定增长，新产品新业务加速落地

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% in the stock price compared to the benchmark index within the next 6 to 12 months [5]. Core Views - The company's medical IT business is experiencing stable growth, with new products and services accelerating their implementation [1]. - The revenue for 2023 is projected at 1,616 million, with a growth rate of 6% year-over-year, while the net profit is expected to be 37 million, reflecting a decline of 14% year-over-year [8]. - The company has secured significant contracts in the healthcare sector, with a notable increase in revenue from its medical IT services, which accounted for 91.56% of total revenue [8]. Financial Summary - Revenue Forecast: - 2023: 1,616 million - 2024E: 1,944 million (20% growth) - 2025E: 2,314 million (19% growth) - 2026E: 2,761 million (19% growth) [4] - Net Profit Forecast: - 2023: 37 million - 2024E: 249 million (578% growth) - 2025E: 340 million (37% growth) - 2026E: 470 million (38% growth) [4] - Earnings Per Share (EPS): - 2023: 0.02 - 2024E: 0.16 - 2025E: 0.22 - 2026E: 0.30 [4] - Cash Flow: - Operating cash flow for 2023 is projected at 158 million, increasing to 459 million by 2026 [4]. Business Development - The company has successfully launched new products in the Internet of Things and smart healthcare sectors, with significant contracts signed for hospital management systems [8]. - The company has integrated its services with major partners like Philips, enhancing its product offerings and market reach [8]. - The customer base has been optimized, with a notable increase in the number of registered healthcare professionals and institutions utilizing the company's platforms [8].